antifungal prophylaxis

Risk factors for invasive fungal infections in adult patients with hematological malignancies and/or stem cell transplant: a systematic review and meta-analysis

mycolabadmin

This comprehensive study analyzed multiple research papers to identify which patients with blood cancers or stem cell transplants are most likely to develop serious fungal infections. The researchers found that patients who previously had a stem cell transplant, those taking corticosteroids, and those with low white blood cell counts face the highest risks. Importantly, the study showed that using antifungal medications as a preventive treatment significantly reduces infection risk in these vulnerable patients.

Clinical Mycology Today: Emerging Challenges and Opportunities

mycolabadmin

Fungal infections are becoming more common because of new medical treatments that suppress immune function, and some fungi are developing resistance to standard medications. However, exciting new antifungal drugs are in development that work in different ways and may be easier to use. The article discusses how doctors need better ways to identify patients at risk, design better clinical trials, and train more specialists to handle these increasingly complex fungal infections.

Catastrophic Cerebral Infarctions in a Pediatric Patient with Acute Lymphoblastic Leukemia Due to Mucorales Infection

mycolabadmin

An 11-year-old girl with leukemia undergoing chemotherapy developed a severe fungal infection called mucormycosis caused by Lichtheimia ramosa. The infection spread rapidly from her sinuses to her eyes and brain, causing multiple blood clots in brain arteries and a massive stroke within just five days. Despite emergency surgery to remove the clots, the infection had progressed too far and the patient sadly did not survive, highlighting how dangerous this fungal infection can be in children with weakened immune systems.

Mycobiome analyses of critically ill COVID-19 patients

mycolabadmin

This study examined fungal infections in severely ill COVID-19 patients treated in intensive care units across Europe. Researchers found that a dangerous mold called Aspergillus fumigatus was more common in patients who died and less common in those treated with azole antifungal drugs. The findings suggest that giving antifungal medications to critically ill COVID-19 patients when they arrive at the hospital might help prevent fungal-related deaths.

Invasive Fungal Disease is Rare in Multiple Myeloma Patients Treated with BCMA CAR-T Therapy

mycolabadmin

Researchers studied 234 multiple myeloma patients who received a cutting-edge cancer treatment called BCMA CAR-T therapy. While this therapy can cause serious side effects related to immune system activation, the study found that dangerous fungal infections were surprisingly rare, occurring in only 1.7% of patients. However, when fungal infections did occur in these patients, they tended to be severe and life-threatening, highlighting the need for careful monitoring of high-risk patients.

Global status and trends of invasive pulmonary aspergillosis: A bibliometric study

mycolabadmin

This study analyzes 24 years of research on invasive pulmonary aspergillosis, a serious fungal infection in immunocompromised patients. Using bibliometric tools, researchers mapped out how the field has evolved, identifying leading countries (USA, Germany, China), key experts like David Denning and Thomas Walsh, and shifting research focus from transplant-related infections to COVID-19-associated cases. The analysis shows the field is rapidly growing with increasing emphasis on rapid diagnostic methods and antifungal therapies.

The Burden of Neonatal Invasive Candidiasis in Low- and Middle-income Countries: A Systematic Review and Meta-analysis

mycolabadmin

This study examined fungal blood infections in newborns across low- and middle-income countries, analyzing data from nearly 11,000 cases. Researchers found these infections occur more frequently and have higher death rates in poorer countries compared to wealthy nations. They identified that most infections are caused by Candida fungus species, and many of these fungi have become resistant to fluconazole, the most commonly used treatment drug.

Liposomal amphotericin B prophylaxis in paediatrics: a systematic review

mycolabadmin

This review examined how well liposomal amphotericin B (a fungal medication) works to prevent serious fungal infections in children. Researchers looked at 20 studies involving over 2000 children and found that about 7% still developed fungal infections despite the medication, with common side effects being low potassium levels and liver problems. The main finding is that doctors use this medication in very different ways, and we need better research to figure out the best dosing strategy for children.

Inappropriate treatment of pulmonary aspergillosis caused by Aspergillus flavus in susceptible pediatric patients: a case series

mycolabadmin

This case series describes three children in Iran who developed serious lung infections caused by a fungal organism called Aspergillus flavus. Tragically, two of the three children died because their infections were diagnosed too late and they did not receive appropriate antifungal medications. The study emphasizes that children with weakened immune systems need quick diagnosis and proper antifungal treatment to survive these dangerous fungal infections.

Liposomal amphotericin B prophylaxis in paediatrics: a systematic review

mycolabadmin

This study reviews how a fungal medication called liposomal amphotericin B is used to prevent serious fungal infections in children with weakened immune systems, particularly those with blood cancers or who have had bone marrow transplants. The researchers found that this medicine prevents infections in about 93% of children, though it does cause side effects like low potassium levels in about 23% of patients. However, the study shows that current use of this medicine is quite varied and more high-quality research is needed to determine the best dosing approach.

Research Keyword: antifungal prophylaxis